最新国内外幽门螺杆菌感染治疗策略解读  

Interpretation of the latest treatment strategy for Helicobacter pylori infection

作　　者：周丽雅[1] 尹志豪 ZHOU Li-ya;YIN Zhi-hao(Department of Gastroenterology,Peking University Third Hospital,Beijing 1000191,China)

机构地区：[1]北京大学第三医院消化科,北京100191

出　　处：《中国实用内科杂志》2023年第4期265-268,286,共5页Chinese Journal of Practical Internal Medicine

基　　金：幽门螺杆菌感染及上胃肠疾病防治研究北京市重点实验室(BZ0371)。

摘　　要：根据最新的《2022中国幽门螺杆菌感染治疗指南》和《幽门螺杆菌感染的处理:MaastrichtⅥ共识报告》提供的治疗策略,幽门螺杆菌感染的首选方案仍为铋剂四联方案。钾离子竞争性酸阻滞剂可替代质子泵抑制剂用于铋剂四联方案。高剂量双联方案疗效与铋剂四联方案相同。部分中药、益生菌可提高铋剂四联方案根除率、减少不良反应。三联方案联合胃黏膜保护剂无法替代铋剂四联方案。According to the latest "Chinese national clinical practice guideline on Helicobacter pylori eradication treatment" and "Management of Helicobacter Pylori Infection:Maastricht Ⅵ Consensus Report",the preferred regimen for Helicobacter pylori infection is still bismuth quadruple therapy.Proton pump inhibitor in the regimen may be replaced by potassiumcompetitive acid blockers.The therapentic effect of high-dose dual therapy is the same as that of bismuth quadruple therapy.Some traditional Chinese medicines and probiotics can increase the eradication rate of bismuth quadruple therapy and reduce adverse effects.Clarithromycin triple therapyplus gastric mucosal protective agents cannot replace bismuth quadruple therapy.

关 键 词：幽门螺杆菌 治疗 策略 

分 类 号：R574[医药卫生—消化系统]